Miller W L, Reeder G S
Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA.
Mayo Clin Proc. 2001 Apr;76(4):391-405. doi: 10.4065/76.4.391.
Survival after myocardial infarction has been improving steadily in recent decades, in part because of more effective adjunctive medical therapies. However, the issue of underutilization of effective medical therapies remains. Adjunctive therapy for acute myocardial infarction should include aspirin, beta-adrenergic blocking agents, angiotensin-converting enzyme inhibitors, and lipid-lowering agents, all of which improve survival in the treatment and secondary prevention of myocardial infarction. This review presents the current knowledge supporting the use of specific adjunctive pharmacologic agents and also discusses the current status of other agents that are emerging or controversial.
近几十年来，心肌梗死后的生存率一直在稳步提高，部分原因是辅助药物治疗更加有效。然而，有效药物治疗未得到充分利用的问题仍然存在。急性心肌梗死的辅助治疗应包括阿司匹林、β-肾上腺素能阻滞剂、血管紧张素转换酶抑制剂和降脂药物，所有这些药物都能提高心肌梗死治疗和二级预防中的生存率。本综述介绍了支持使用特定辅助药物的现有知识，并讨论了其他正在出现或存在争议的药物的现状。
